Becton, Dickinson and Company (BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day Transcript

Core Insights - Becton, Dickinson and Company (BD) is actively pursuing a review strategy for its Biosciences division following significant developments in its first quarter report [4]. Group 1: Company Strategy - The company has been heavily investing in technology over the past decade, indicating a long-term commitment to innovation and improvement in its operations [6]. Group 2: Conference Context - The discussion is part of Citi's Unplugged Medtech and Life Sciences Tools Day, highlighting the importance of investor engagement and communication regarding company strategies and performance [1].